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Abstract 
Background: Qualitative research has a key role to play in biomedical innovation projects. This article focuses on 
the appropriate use of robust social science methodologies (primarily focus group studies) for identifying the public’s 
willingness and preference for emerging medical technologies. Our study was part of the BloodPharma project (now 
known as the Novosang project) to deliver industrially generated red blood cells for transfusion. Previous work on 
blood substitutes shows that the public prefers donated human blood. However, no research has been conducted 
concerning attitudes to stem cell derived red blood cells.
Method: Qualitative research methods including interviews and focus groups provide the methodological context 
for this paper.
Results: Focus groups were used to elicit views from sub-sections of the UK population about the potential use of 
such cultured red blood cells. We reflect on the appropriateness of that methodology in the context of the BloodP-
harma project. Findings are in the form of lessons transferable to other interdisciplinary, science-led teams about what 
a social science dimension can bring; why qualitative research should be included; and how it can be used effectively.
Discussion: Qualitative data collection offers the strength of exploring ambivalence and investigating the reasons for 
views, but not necessarily their prevalence in wider society. The inherent value of a qualitative method, such as focus 
groups, therefore lies in its ability to uncover new information. This contrasts with a quantitative approach to simply 
‘measuring’ public opinion on a topic about which participants may have little prior knowledge. We discuss a num-
ber of challenges including: appropriate roles for embedded social scientists and the intricacies of doing upstream 
engagement as well as some of the design issues and limitations associated with the focus group method.
Keywords: Cultured red blood cells, Public engagement, Participatory research, Interdisciplinarity, Focus groups, 
Interviews, Qualitative research, Upstream engagement
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Introduction
Social scientists have previously studied blood in the 
contexts of the ‘gift relationship’ [1] and the ‘biovalue’ 
of blood [2], situated within the wider field of tissue and 
organ donation and the role of altruism within blood 
transfusion. While other groups have studied blood 
replacement technologies [e.g., 3], no previous research 
has been conducted concerning public attitudes to stem 
cell derived red blood cells. Working as part of an inter-
disciplinary research collaboration, involving natural 
scientists, clinicians and engineers (the ‘BloodPharma 
project’ [4]), we conducted an empirical study using qual-
itative research methods, from which we derive lessons 
transferable to other interdisciplinary teams about why, 
when and how to engage members of the public around 
willingness and preferences of emerging medical tech-
nologies. Our study of cultured red blood cells serves as 
an illustrative example of innovation projects within the 
emerging field of regenerative medicine more broadly; a 
field surrounded by considerable high expectation, and 
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which is regarded as susceptible to translational chal-
lenges including, in particular, those related to public 
perceptions and concerns.
This article reports on the methodology we used in 
our study. Our purpose here is threefold. First, we argue 
for adopting qualitative, focus group research as a use-
ful method for engaging purposively sampled groups in 
the development of biomedical innovations. We reflect 
on key research design issues and lessons learned from 
the process that could be transferable to other teams of 
scientists and clinicians seeking to work with embedded 
social scientists in order to gauge potential public reac-
tions to new medical technologies.
There is an on-going debate within the social science 
community about appropriate roles for the social sci-
ences in interdisciplinary, science-led collaborations, 
with increasing calls for social researchers to be involved 
in the earliest, problem-framing and agenda-setting 
phases of such research [5]. Our second purpose is to 
extend this debate to biomedical and other natural scien-
tists, whom we anticipate will form the primary audience 
for this paper.
Thirdly, having witnessed the movement over the 
past 20 years from education, to participation, and now 
to much earlier public consultation over emerging sci-
ence and technology, as methods of increasing the pub-
lics’ trust in science, our findings also underscore the 
challenges of doing this so-called ‘upstream engage-
ment’ [6] in such fields. The BloodPharma team is car-
rying out upstream engagement well before the cultured 
blood product is expected to reach the clinic (potentially 
20  years from now). Upstream engagement presents a 
significant challenge to the BloodPharma team, due to its 
unique position in already having the viable alternative 
of blood donation. Unlike other entirely new technolo-
gies being developed using regenerative medicine, which 
may provide a unique benefit, the BloodPharma prod-
uct is a reformulation of an existing technology—blood 
from donors. The public is therefore not being asked to 
accept a new product but to choose between the exist-
ing (trusted and familiar) blood from human donation 
and the new BloodPharma product. This presents par-
ticular difficulties in explaining why this change is neces-
sary: as one of our interviewees put it, they are ‘creating a 
demand, not filling a need’.
Background
Blood donations are now widely used in Western medical 
care to overcome blood loss through injury, during sur-
gery, or for those conditions that result in severe anaemia 
[7]. Currently, this blood supply is dependent on many 
human blood donors. The UK is fortunate in possessing 
an established donation system, although fluctuations in 
donor numbers do occur, and even in established blood 
donation systems there is the potential for transfusion-
transmitted infections (TTIs). The BloodPharma project 
is therefore developing an alternative method of pro-
ducing red blood cells (RBCs) for use in human transfu-
sion, using stem cell technology, with the eventual aim 
of producing an unlimited, and infection-free, supply of 
O rhesus negative (the universal donor) RBCs. Previous 
attempts by other research teams to culture blood from 
other means (e.g., bone marrow and cord blood) have not 
proved successful [8].
Development of a novel method of obtaining red blood 
cells for transfusion cannot become a substitute for 
conventional blood donation unless the factors deter-
mining uptake are understood. Trust is seen to have a 
direct impact on the acceptance of technologies, which 
in turn impacts on how many people are willing to use 
such technologies and on their potential market value [9, 
10]. The EuroBloodSubstitutes project [3] represents one 
of the few examinations of public attitudes to the use of 
blood replacement technologies but did not include stem 
cell derived technology. Although the findings from the 
EuroBloodSubsitutes study demonstrated that alterna-
tives to donated blood were perceived as ‘more risky’ by 
the public, there is little basis on which to judge how the 
public may react to the use of cultured red blood cells 
from stem cells. Our research therefore sought to elicit 
the views of a wide variety of publics towards the poten-
tial use of cultured RBCs for transfusion. As a result, we 
were able to offer the BloodPharma team specific recom-
mendations regarding their future interactions with the 
public and potential users of the BloodPharma product 
[11].
Reasons for eliciting public views
A key driver of the BloodPharma outreach is to engage 
members of the public early in the innovation of the cul-
tured blood product, given evidence [e.g., 12–15] that 
suggests that patient and clinician views can impact on 
the uptake of new therapies. There are several reasons for 
engaging wider publics in the development of scientific 
research, which include widening expertise, developing 
information resources, social responsibility, risk manage-
ment, and gaining public acceptance. For many projects, 
including the BloodPharma project, the motivations for 
undertaking public engagement may touch on all of these 
reasons.
Studies have demonstrated public unease that scien-
tists lack regulatory oversight, and highlight the role 
that an understanding of regulation can play in build-
ing trust between publics and researchers in the area of 
stem cell technology [e.g., 10]. This taps into wider calls 
for scientists to step down from the ‘ivory tower’ [16] 
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and attempts to bring engagement with lay audiences 
‘upstream’ in order to increase public trust in science 
[6]. The broader context for this spans both the long-
standing science and technology studies literature, which 
understands innovation to be a complex, interactive pro-
cess rather than one that follows a linear model (see, for 
example, [17]), and the more recent discourse around 
‘Responsible Research and Innovation’ (launched by the 
European Commission as part of the Horizon 2020 pro-
gramme [18]), which argues that innovation needs to be 
attentive to, and directed towards, the values and per-
spectives of the public.
The criteria for obtaining research funding also often 
force researchers to identify at an extremely early stage 
aspects such as target markets, potential patient groups, 
specific details about the eventual product, etc. It is rec-
ognised that such expectations are crucial for mobilising 
funding and that these expectations link technical and 
social considerations [19].
One reason for engaging the views of those outside the 
BloodPharma project was to tap into the wealth of exper-
tise held by different groups. As we explain below, we 
sought to include a range of what might conventionally 
be regarded as ‘lay’ and ‘expert’ views in our data collec-
tion. This, for example, included patient groups who may 
be experts at living with a blood disorder and ongoing 
treatment. Such individuals may not consider themselves 
to have formal expertise but the value of such lay knowl-
edge is increasingly recognised [e.g., 20].
There are, however, differences of opinion on the extent 
to which ‘the public’ should be involved in decision-mak-
ing regarding the implementation of new technology. 
Stem cell therapies are not without risks, such as possi-
ble contamination and the formation of teratomas [21]. 
Each individual has their own definition of acceptable 
risk, resulting in ‘risk cultures’ [22]. The potential risks in 
the stem cell field have been characterised into ‘individ-
ual risks’ (such as the potential for tumour formation or 
stimulation of latent viruses) and ‘community risks’ (such 
as the transfer of animal viruses to the human popula-
tion through the stem cell manufacture) [23]. This leads 
to debates about the role of ethical or moral values in the 
risk analysis of new technologies, and concerns that this 
might override the use of unbiased scientific assessment 
[24–27]. Upstream engagement may inevitably result in 
the restriction of some scientific innovations because 
debate must occur before all the evidence is available 
[28].
The introduction of new drugs and therapies involves 
not just the granting of a marketing authorisation but 
also an element of public willingness to accept the new 
therapy. In places such as the UK, a decision must be 
made about whether a drug or therapy is acceptable for 
use in NHS clinics and hospitals, based largely (but not 
solely) on economic factors. There is increasing evi-
dence that public acceptance plays an important role in 
the delivery of a new technology to market [29]; differing 
uptake rates of new therapies in different countries can-
not be explained by health spending alone [30] and many 
decisions on implementing new therapies fall to clini-
cians, either at individual or at health board level [31].
Public opinion is an important consideration when 
developing new stem cell therapies as the potential 
uptake of the product or therapy can be greatly influ-
enced by the attitudes of the end user (be they the 
recipient of the RBCs, the clinician, or NHS procure-
ment). However, gauging that public opinion, for exam-
ple through surveys, can be problematic in areas where 
there is considerable uncertainty either because the sub-
ject matter is quite technical or because its likely appli-
cation is not yet certain. Focus groups are an especially 
useful method for generating discussion and exchange 
of views in this context when the topic is not something 
that might be widely discussed or known about. They 
are, nevertheless, not unproblematic in terms of how the 
data generated embody the differences between opinion, 
views and beliefs and how this relates to what ‘counts’ as 
evidence, experience and lay expertise.
Methods
Our research adopted a qualitative method which is 
often characterised by its inductive relationship between 
data and theory: data are used to derive theory, in con-
trast to the hypothesis-testing approach more com-
monly favoured by quantitative research methods [32]. 
Our approach does not claim to discover the views of the 
whole ‘public’ but to produce in-depth results about a 
small number of groups.
Our research brought together groups of people who 
were not targeted for any specific expertise in science, 
and who represented a range of ages, level of educational 
attainment, geographical location, etc. We used purpo-
sive rather than probabilistic sampling1 so, although we 
attempted to gather data from a wide variety of demo-
graphic groups, these results cannot be extrapolated to 
cover the whole population of the UK.
Four core groups were identified and data collection 
was carried out with members of these groups across 27 
separate sessions (15 individual interviews and 12 focus 
groups):
  • Patients who were regular users of donated blood 
undergoing multiple transfusions for the treatment of 
1 Readers unfamiliar with social research methods may find a text such as 
Bryman [33] helpful if further definitions are required.
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conditions such as thalassaemia and myelodysplasia 
(MDS)
  • Representatives of religious and moral groups who 
could contribute to the discussion of issues regard-
ing cultured red blood cells from a religious or ethical 
standpoint
  • Clinical groups including nurses and doctors who 
have the potential to use this blood in the course of 
their clinical work
  • Community groups chosen to represent a spread of 
publics, without necessarily having any background 
in science or healthcare. These were recruited 
through sports club, craft groups, etc., and were an 
attempt to represent, as far as possible, the ‘general 
public’.
In this study we used interviews for targeted partici-
pants, chosen because they had a particular knowledge 
base. These included representatives of religious organi-
sations, academics, and doctors. Interviews were also 
conducted with patients who were too geographically 
spread, or not in good enough health, to attend a focus 
group.
Focus groups took a variety of formats. Our stand-
ard focus group lasted approximately 2 h. This incorpo-
rated a time for giving information about the project, 
for discussion, and for activities, as well as a break for 
refreshments. In many of the focus groups, we asked par-
ticipants to write down words that they associated with 
blood as a prompt for further discussion. Whilst this was 
the desired format of the group it was not always possi-
ble to recruit participants for 2-h sessions and, in some 
cases, they were truncated to fit the time available by, for 
example, omitting the writing activity. In a small number 
of cases, we had to adapt to circumstances and conduct 
focus groups with a smaller number of participants for 
durations of just a few minutes each. Focus groups took 
place at a variety of public locations, including meeting 
rooms in local council venues, university rooms, a resi-
dential care home for the elderly, and a further education 
college.
In a focus group, the researcher’s role is to act, not 
as an interviewer, but as a moderator of the discussion 
between participants. Focus group schedules (which pro-
vide an ‘aide memoire’) for this project were designed 
following preliminary scoping conversations with the 
wider project team, an initial review of the literature, and 
on the results of a small number of pilot interviews. This 
prepares the researcher with a list of questions or themes 
to guide the discussion (known as ‘probes’), whilst allow-
ing freedom to change the order of topics, insert new 
ones, or abandon some—depending on how the conver-
sation progresses.
Consent procedures for participants followed the 
guidelines of the School of Social and Political Science, 
University of Edinburgh [34]. The majority of par-
ticipants were consented using signed consent forms 
before data collection took place. Where this was 
not appropriate (for example, the focus groups with 
parents at a toddler group) then verbal consent was 
obtained.
All interviews and focus groups were recorded then 
transcribed verbatim2 but with the removal of filler words 
(‘like’, ‘actually’), non-verbal utterances (‘ummm’, 
‘hmmm’) and general chat, where these were not deemed 
to add anything to the data. To protect confidentiality, 
pseudonyms were used to identify participants in all 
transcripts. Data analysis for this project then followed a 
grounded theory methodology [35], which allows for 
data collection to take place iteratively, with earlier find-
ings contributing to questions asked during future data 
collection.
The identification of key themes in qualitative data 
analysis is a process of pattern recognition and data 
reduction. ‘Coding’ is a process of identifying these key 
themes as they occur in the data, in this case in tran-
scripts of interviews and focus groups, and was under-
taken using NVivo software. The key themes chosen for 
coding were identified at the outset of the project (by 
the team and through the research questions) and aug-
mented by themes that arose during the preliminary 
interviews and further data collection.
As reflexive social scientists, we then undertook a 
process of reflection and discussion among the research 
team and with other colleagues in order to consider 
both our methods and the results they had produced. 
This enabled us to assess the outcomes from our 
engagement in this biomedical project from the per-
spectives of, inter alia, any disparities between our ini-
tial expectations and eventual outcomes, the logistical 
challenges of undertaking this type of research, and our 
own experiences as social scientists working as part of a 
predominantly biomedical team. From this we were able 
to derive a series of lessons about the design and con-
duct of such research that we believe would have utility 
in future interdisciplinary, biomedical innovation pro-
jects. Our intention in doing so is not to offer a checklist 
or protocol for qualitative research methods as others 
have done (e.g. [36]) but to discuss some of the moti-
vations, challenges and benefits of such an approach in 
the context of interdisciplinary research teams in order 
to ensure the appropriate involvement of social science 
expertise [5].
2 The only exception to this was a small number of focus groups where 
handwritten notes were taken.
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Research design decisions
Choosing interviews or focus groups
Both interviews and focus groups are qualitative research 
methods that are designed to extract in-depth informa-
tion from participants. They are similar in the potential 
topics covered, the process of consent, and the methods 
of recruitment. Interviews are conducted with one, or 
sometimes two, participants. The researcher takes the 
position of interviewer, and asks questions and elicits 
responses from the participant (interviewee). Interviews 
can be structured, semi-structured, or unstructured in 
design [33, 37]. Focus groups are carried out with a larger 
number of people, ideally four to six participants. The 
aim of a focus group is to study the discussions within the 
group, and the researcher is considered to be the mod-
erator or facilitator, rather than an interviewer [38, 39]. 
The moderator will pose questions and generally chair 
the discussion, but the aim is to generate discussion 
among participants, rather than a back and forth dia-
logue between participants and moderator.
A key research design decision that must be made in a 
study of this type is whether it is more appropriate to use 
interviews or focus groups as the main data collection 
method. In searching the literature (e.g. [40]) and asking 
advice of colleagues, there were three key considerations 
that determined our choice of method:
  • interviews are more appropriate for participants who 
have a pre-existing knowledge base about the topic 
being researched whereas focus groups are better for 
people who may not have prior knowledge of the topic
  • interviews are generally easier to recruit and plan as 
it only involves the coordination of the participant 
and the researcher
  • interviews offer higher levels of anonymity compared 
with focus groups. Although consent procedures are 
fully adhered to for both methods, there is the addi-
tional factor of the other participants present at a 
focus group
Choosing participants
These three points therefore determined the method that 
we selected for different participants, for example:
  • we used interviews for ‘expert’ participants, e.g., the 
representatives of religious organisations, academics, 
doctors
  • we used interviews for people whom we found it 
hard to recruit due to busy schedules, e.g., haema-
tologists
  • we used interviews with patients who were scat-
tered around the country and not part of an existing 
patient group
  • we used focus groups for ‘lay’ participants—such as 
the groups recruited through sports clubs, students, 
parent and toddler groups
  • we used focus groups where we could bring together 
existing groups, e.g., patient groups.
The aim of the data collection was not to achieve a rep-
resentative sample of the entire UK population,3 but 
instead to concentrate on obtaining the views of as wide a 
range of groups as possible. In order to achieve this, we 
attempted to obtain a representation of both rural and 
urban populations, a variety of ages, variation in educa-
tional attainment, etc.4 Some participant groups were 
targeted due to the perceived information that they could 
bring to the discussion, for example patients and reli-
gious groups.5 Other groups were considered representa-
tive of the ‘general’ population—for example those focus 
groups conducted with sports clubs. We had hoped to 
engage more religious groups, and groups of interna-
tional students but this was hindered by the lack of gate-
keepers who were willing to facilitate access for us. 
Middle-aged men and blue-collar workers are also nota-
bly under-represented in our sample.
Known or unknown groups
A consideration in focus group recruitment is whether to 
use groups of individuals who are already known to each 
other (i.e., social groups) or whether to convene groups 
of individuals who have not previously met. Known (pre-
existing) groups are likely to require fewer ice-breaking 
exercises as the participants are already known to each 
other. This can help to put people at their ease. The 
downside of using known groups is considered to be the 
presence of already established hierarchies and relation-
ships within the group. In discussions about personal 
or contentious topics, pre-existing groups may suppress 
conversations if people do not want to reveal things to 
people already known to them—and whom they will see 
after the focus group. Pre-existing groups are also consid-
ered easier to recruit. Unknown groups may encourage 
more openness for certain people or topics, but are con-
sidered more difficult to recruit.
3 Due the nature and funding of the BloodPharma project, data collection 
was focused within Scotland. In one case (the Thalassaemia group), it was 
not possible to obtain a large enough number of patients in Scotland, and so 
this took place in England.
4 It was not possible for demographic information, including gender and 
age, to be taken at every focus group but information that was collected 
showed a slightly higher proportion of males to females; participants’ ages 
ranged from 18 to 80+.
5 It was decided to limit the involvement of GPs and other health service 
workers as their views had already been sought in a previous report com-
missioned by the BloodPharma project [41].
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In this research we primarily used pre-existing groups. 
This was due to the nature of the organisations who acted 
as gate-keepers for us (for example, patient groups) and 
for speed of recruitment. It was felt that the nature of the 
topic being discussed did not prevent participants from 
sharing information with the group, and that the reliability 
of recruiting established groups outweighed any potential 
negatives. Some groups (such as the medical students) had 
participants who were not known personally to each other, 
but who studied together at the same medical school. Our 
only ‘unknown’ group resulted in only one participant 
attending, giving weight to the idea that organising groups 
of people who are known to each other provides more of a 
social obligation for people to attend.
Reporting data
Focus groups analyse the interactions between partici-
pants, and every effort should be made to represent this 
in data analysis [32, 42]. This means that conversations 
between participants are analysed and reported, and the 
use of single quotations from the transcript is avoided.
In reporting qualitative data, key themes are identi-
fied by the researcher, but are taken from the data gath-
ered during interviews and focus groups. This means 
there may be factual inaccuracies present, but these are 
a representation of what participants believe to be true. 
Additionally, as is common when conducting a range of 
different focus groups, many of the responses might be 
considered rather contradictory (for example, in our 
dataset, participants were against the commercialisation 
of blood product, whilst recognising the needs of com-
mercial companies in producing pharmaceuticals; simi-
larly, one respondent was accepting of the use of hESC 
in research into IVF, but against hESC use for other 
research purposes).
Lessons learned and recommendations
In many respects, our experience of working in the 
BloodPharma partnership reflects one of the classic 
interdisciplinary challenges when an already established 
natural science project decides to incorporate a social 
science element (e.g., [43]). In such circumstances, social 
scientists are often brought into ask the ‘how’ questions 
rather than the ‘why’ questions: in this case, ‘how will the 
public respond?’.
This approach risks reducing the social science input 
to a service or subordination role [43] where the social 
researchers provide specific, well-defined inputs (such as 
‘public engagement’) to another domain without the need 
for significant interdisciplinary interaction or contribu-
tion to advance their own core disciplinary knowledge. In 
such cases, social scientists may feel they are regarded as 
mediators rather than as scholars in their own right [44].
The often idealised accounts of cross-disciplinary 
interaction (criticised in [45]) do not necessarily prepare 
scientists and clinicians well for the experience of inter-
acting with social researchers: both research funders and 
project leaders need to set aside time and resources at the 
outset of such collaborations to ensure maximum value 
from these interactions [46, 47].
The second lesson we would proffer is to ‘expect the 
unexpected’ and not to assume that public consultation 
will only confirm what you already know. At the outset 
of this study, we had anticipated that the use of embry-
onic stem cells in the early stages of the research would 
be a barrier to public acceptance of the cultured blood 
product. However, this technology was acceptable for the 
majority of people to whom we spoke, whereas it was the 
commercial aspect of the BloodPharma project, which 
might alter the nature of blood from a ‘gift’ to a commer-
cial commodity, that garnered the most concerns [11]. 
This reinforces the added value of a qualitative method, 
such as focus groups, in terms of generating new infor-
mation, rather than a quantitative approach to simply 
‘measuring’ public opinion, on a topic about which par-
ticipants may have little prior knowledge. Nevertheless, 
there are limitations with this method, most notably the 
challenge of translating data into policy and practice 
when the sampling may be purposive rather than statisti-
cally representative of whole populations.
Thirdly, issues of informed consent will always be a 
major consideration in research of this type. We had 
opted to obtain Level 2 ethical consent from the Univer-
sity of Edinburgh as we sought to engage with partici-
pants who had particular medical conditions. However, 
we decided not to recruit through clinics, in part because 
this would have required the more stringent (and time-
consuming) NHS ethics approval but also, significantly, 
because we did not want to involve patients who were 
under pressure during times of illness. For our particu-
lar research project, we were steered away from recruit-
ing participants from blood donation sessions, (which 
would have been an obvious gateway), due to sensitivities 
on the part of the blood transfusion service surround-
ing any unintended impressions that donors might gain 
regarding any potential future reduction in the need for 
donors. Similar research in other areas of new medical 
technology might present their own unique sets of cir-
cumstances, intensifying the challenges of obtaining ethi-
cal approval.
Our fourth set of lessons relates to access and design 
choices, summarised in Table 1. Given that we had opted 
for a greater use of ‘known groups’ in our recruitment 
strategy, we relied heavily on the co-operation of various 
gatekeepers to provide access to potential participants 
but we encountered difficulties with recruitment beyond 
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what we had anticipated at the start of the project. This 
led to a number of groups whom we had hoped to engage 
being dropped from our data collection within the time-
frame of our project. The lesson we draw from this is to 
plan for longer lead times and to consider the pros and 
cons of identifying key individuals who may be able to 
facilitate introductions to such groups.
Many of the patients were recruited through gate-
keeping organisations such as patient groups. It became 
apparent that many of these groups are run by resource- 
and time-limited volunteers and our request was very 
far down their priority list. In one case, it took over a 
year from first contact to the gatekeeper putting us in 
touch with potential patients. Some of the charities also 
declined to let us access or post anything on Facebook 
or blog pages, and insisted that our project proposal, and 
the work of the BloodPharma project, were reviewed by 
their own medical advisers.
Many groups simply failed to respond to any contact 
made, despite numerous reminders from the researchers. 
We also encountered a number of gatekeepers who were 
unfamiliar with social science data collection methods. 
These included academic departments such as medical 
schools that required us to obtain their own ethical con-
sent, the wording of which was not applicable for social 
science data collection methods.
Difficulty in obtaining participants for social science 
research is not unusual, although this normally happens 
at the level of the actual focus groups. For example, the 
literature normally recommends over-recruiting [48], to 
allow for people not attending at the allocated time. Our 
experience was that we had no last-minute non-attend-
ance at the groups we had organised (other than the 
group of unknowns, reinforcing what has already been 
established in the literature about the difficulty of recruit-
ing such groups), but that the original organisation of 
these groups through the gatekeepers was the main bar-
rier to data collection.
Finally, there are broader problems in applying 
upstream engagement to new medical technologies: con-
flict may arise from a complex mixture of uncertainty, 
power politics, divergent societal interests, values and 
ideologies, and commercial competition. Upstream 
engagement can create opportunities to reinforce the 
negative views of new technologies where, as we have 
discussed elsewhere [49], there may be no societal con-
sensus about whether we should develop particular tech-
nologies. Engagement should be carefully timed: too 
early (‘upstream’) and its value will be undermined by 
uncertainty about the nature of future developments; too 
late and stakeholder opinions and political positions may 
have become entrenched so that accommodation will be 
more difficult to achieve.
Conclusions
We have demonstrated that qualitative research and, 
specifically, focus-group studies have a key role as part 
of interdisciplinary, biomedical innovation projects. We 
have identified generalisable lessons that will further 
the clinical research community’s ability to enlist robust 
methodologies for identifying the public’s willingness 
and preference for emerging medical technologies. Spe-
cifically, this study enabled people to ask questions about 
the BloodPharma project and to voice any concerns. Data 
gained from these focus groups will contribute to the 
design and delivery of project information, for example, 
through the BloodPharma (now Novosang) website.
Notably, our difficulty in recruitment speaks to a wider 
question about why we should expect the public to 
engage in medical and scientific research, and to give up 
their time in order to do so. This is echoed in the pub-
lic engagement literature [e.g., 50] which is moving from 
an emphasis on engaging the public to a more reflective 
look at why and how the public should be engaged, and a 
growing recognition of why the public may (or may not) 
want to engage with science.
Nevertheless, our experience offers a number of prac-
tical lessons regarding the design and conduct of such 
research that should help teams of scientists and clini-
cians maximise the value of future engagements with 
public audiences through social science research.
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